hANGPTL3(4)
品系全名
C57BL/6JSmo-Angptl3tm1(hANGPTL3)Smoc
目录号
NM-HU-210036
品系状态
活体
基因信息
基因名
Angptl3
品系描述
验证数据
Fig1. Detection of ANGPTL3 expression in liver by RT-PCR.
Wild type: only one band at 187 bp with primers F1/R1(mAngptl3);
Homozygous: only one band at 138 bp with primers F2/R2(hANGPTL3);
Abbr. M, DNA marker; HO, homozygous; HE, heterozygous; WT, wild type.
Fig.2 Detection of mANGPTL3(A) and hANGPTL3(B) expression in serum by ELISA.
Abbr. HO, homozygous; WT, wild type.
Note. The HO hANGPTL3 mice was 12 weeks old, female.
Fig3. Detection of hANGPTL3 expression in serum in homozygous hANGPTL3 mice by ELISA.
Abbr. HO, homozygous
Fig.4 Monitoring of serum blood lipids levels in male hANGPTL3 mice (n=3) (In cooperation with the third party).
Abbr. Hom, homozygous; WT, wild type.
Fig.5 Monitoring of serum blood lipids levels in female hANGPTL3 mice (n=2) (In cooperation with the third party).
Abbr. Hom, homozygous; WT, wild type.
Fig.6 hANGPTL3 mice (male, 8-10 weeks old) were randomly divided into two groups (n=8/group). Mice were administered with ARO-ANG3, a nucleic acid drug targeting ANGPTL3, synthesized according to the relevant patents. Blood lipids level of hANGPTL3 mice before or after dosing were detected.
Compared to vehicle, ARO-ANG3 treatment group showed a significant decrease in TG, T-CHO and HDL-C. Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.
Fig.7 hANGPTL3 mice (male, 8-10 weeks old) were randomly divided into two groups (n=8/group). Mice were administered with ARO-ANG3, a nucleic acid drug targeting ANGPTL3, synthesized according to the relevant patents. At day 29 post-dosing, the mice were euthanized, and their livers were collected for the assessment of human ANGPTL3 mRNA expression via qPCR.
The results indicated a significant reduction in human ANGPT3 expression in the ARO-ANG3 treatment group compared to the vehicle control. Mean ± SEM. t-test, ***P < 0.001.
Fig.8 hANGPTL3 mice (male, 8-10 weeks old) were randomly divided into two groups(n=8/group). Mice were administered with ARO-ANG3, a nucleic acid drug targeting ANGPTL3, synthesized according to the relevant patents. Expression level of hANGPTL3 before or after dosing at indicated timepoint was detected by ELISA.
Compared to vehicle, ARO-ANG3 treatment group showed a significant decrease in the expression of hANGPT3. Mean ± SEM. t-test, ***P < 0.001.
你也可能感兴趣
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
